ⅡB~Ⅲ期食管癌根治术后预防性放疗疗效分析
DOI: 10.3971/j.issn.1000-8578.2018.17.1207
Keywords: A Meta-analysis,Value of 18F-FDG PET/CT in Evaluating Chemotherapeutic Effect of Diffuse Large B Cell Lymphoma Patients with Different CD5 Expression,Advances in Prognostic Value of Peripheral Blood Inflammatory Indexes in Non-small Cell Lung Cancer,Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castrationresistant Prostate Cancer Patients,Cholesterol: A Predictor of Risk and Prognosis of Breast Cancer,Predictive Value of Preoperative Hematologic Inflammatory Markers in Prognostic of Glioma Patients,Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix,Effect of Marital Status on Survival of Lung Cancer Patients Investigated Based on SEER Database,Clinical Characteristics and Prognosis of Primary Thyroid Lymphoma Patients,Prognostic Factors and Comprehensive Treatment of 95 Synovial Sarcoma Patients,Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients
Abstract:
摘要 目的 探讨术后预防性放疗对ⅡB、Ⅲ期胸段食管癌根治术患者生存的影响。方法 收集2007—2010年本院行食管胸段鳞癌根治术患者336例，其中ⅡB期65例、Ⅲ期271例；术后未行放疗组（S）220例，术后放疗组（S+R）116例；放疗中位剂量50 Gy。采用Kaplan-Meier法计算生存率及局控率；Log rank法检验行单因素预后分析。结果 随访率为98.2%，全组患者5年生存率及5年无进展生存率分别为29.3%和25.6%；中位生存时间及中位无进展生存时间分别为26.7月和17.4月。ⅡB期患者S组与S+R组5年生存率分别为30.1%与48.6%，差异无统计学意义（χ 2=2.279, P=0.131）；Ⅲ期患者S组与S+R组5年生存率分别为24.9%与32.8%，差异有统计学意义（χ 2=5.865, P=0.015）；术后病理淋巴结阳性患者S组与S+R组5年生存率分别为25.9%与35.8%，差异有统计学意义（χ 2=7.663, P=0.006）；全组患者S组与S+R组的中位局控时间分别为10.6和16.3月，差异有统计学意义（χ 2=6.043, P=0.014）。结论 食管癌根治术后预防性放疗可明显降低局部复发并使Ⅲ期及术后病理淋巴结阳性的患者生存获益
Full-Text
